Viewing Opinion | StockChase
Abbott Labs (ABT-N) opinion on 2017-05-17

Last Price Recorded: 55.8000 on 2017-11-23

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical
TOP PICK

Cameron Hurst
Abbott Labs was $43.080 at time of opinion
Owned : Yes

Healthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)

UNKNOWN

All opinions for ABT-N (106)

30 BUY
5 BUY on WEAKNESS
17 COMMENT
7 DON'T BUY
6 HOLD
14 PAST TOP PICK
1 SELL
1 SELL ON STRENGTH
23 TOP PICK
2 WAIT
View All

More experts covering ABT-N

SAVE
Add ABT-N to Watch List

All opinions for ABT-N (106)

30 BUY
5 BUY on WEAKNESS
17 COMMENT
7 DON'T BUY
6 HOLD
14 PAST TOP PICK
1 SELL
1 SELL ON STRENGTH
23 TOP PICK
2 WAIT
View All

More experts covering ABT-N

SAVE
Add ABT-N to Watch List

No Comments.


You must be logged in to comment.

Successfully Saved Company